Oncolytics Biotech (ONCY) Tops Q1 Loss Views by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ONCY Hot Sheet
Join SI Premium – FREE
Oncolytics Biotech (NASDAQ: ONCY) reported Q1 loss of ($0.06), $0.03 better than the analyst estimate of ($0.09).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oncolytics reports pelareorep HPV immune response data in anal cancer
- Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers
- Reservoir Media, Inc. (RSVR) Tops Q2 EPS by 2c; offers guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
